Skip to main content
Transparent prices. Guidance you can trust. Our manifesto
Build my panel

Colon Cancer Blood Test: Can a Blood Test Screen for Colon Cancer?

Yes, two FDA-approved blood tests, Shield and SimpleScreen CRC, screen for colorectal cancer in average-risk adults 45 and older. They find about 4 in 5 cancers but only about 1 in 8 advanced precancerous polyps, so the American Cancer Society ranks them below stool tests and colonoscopy, and a positive result always needs a colonoscopy.

Published
November 15, 2026
Read time
12 min read
Medically reviewed by
Rhonda Collins Rhonda Collins, FNP-C

Share

Summarize with AI

A lone runner on a wide sandy beach at the water line, under a clear sky at golden hour.
Table of contents

Yes, there is a blood test for colon cancer screening, but it is not the best one. The FDA has approved two blood tests that screen for colorectal cancer, Shield and SimpleScreen CRC, for adults 45 and older at average risk [1][3]. In their main studies they found about 4 in 5 colorectal cancers but only about 1 in 8 advanced precancerous polyps [2][4]. Blood tests are less effective at detecting advanced precancerous polyps, so the American Cancer Society (ACS) lists them as a fallback for people who will not do a stool test or a visual exam [5]. A positive blood test always has to be followed by a colonoscopy, and no blood test replaces one [1][3].

Other blood tests answer different questions. Multi-cancer tests such as Galleri look across many cancers at once and add to colorectal screening rather than standing in for it. CEA tracks a cancer that has already been diagnosed. A routine complete blood count (CBC) or ferritin test can show iron deficiency anemia, which is sometimes the first clue to a bleeding colon cancer [15].

The short answer

  • Blood-based colorectal screening exists. Shield (Guardant Health) and SimpleScreen CRC (Freenome) are FDA approved for average-risk adults 45 and older without symptoms [1][3].
  • It catches most cancers and few precancerous polyps. Shield found 83% of cancers and 13% of advanced precancerous lesions in its pivotal study. SimpleScreen CRC found 79% and 12.5% [2][4].
  • Guidelines rank it last. The ACS calls blood-based tests “not preferred” [5]. The US Preventive Services Task Force (USPSTF) 2021 recommendation does not include serum tests among its screening strategies [7].
  • A positive result means colonoscopy. Colonoscopy is also the only test that removes polyps during the same procedure.
  • Mito does not sell Shield, SimpleScreen CRC, FIT or stool DNA tests. Guideline colorectal screening goes through your own clinician or insurer. Mito offers Galleri, CEA and the routine blood tests described below.

What is the Shield blood test, and who is it for?

Shield is a blood test that looks for colorectal cancer signals in cell-free DNA, the small fragments of DNA that cells release into the bloodstream. The FDA approved it in July 2024 for colorectal cancer screening in people at average risk, age 45 or older [1]. Its approved labeling sets three limits [1]:

  • people with a positive result should be followed by colonoscopy;
  • it is not a replacement for diagnostic colonoscopy, the kind done to investigate symptoms;
  • it is not a replacement for surveillance colonoscopy in high-risk people, such as those with a history of polyps or colorectal cancer.

In July 2026 the FDA approved a change that moved Shield to a methylation-only model [1]. A second blood test, Freenome’s SimpleScreen CRC, was approved in July 2026 with the same intended population and the same three limits [3].

Medicare covers an FDA-approved blood-based colorectal screening test once every 3 years for people aged 45 to 85 who have no symptoms and are at average risk, with no cost to the patient when the provider accepts assignment [10].

How accurate is a colon cancer blood test?

A colon cancer blood test finds most cancers that are already present but misses most of the precancerous growths that screening is meant to catch early. In both pivotal studies, every participant also had a colonoscopy, which served as the reference.

StudyTestParticipantsSensitivity for colorectal cancerSensitivity for advanced precancerous lesionsSpecificity
ECLIPSE (NEJM 2024) [2]Shield7,86183.1%13.2%89.6% for advanced neoplasia
PREEMPT CRC (JAMA 2025) [4]SimpleScreen CRC27,01079.2%12.5%91.5% for advanced neoplasia

What those numbers mean in practice:

  • About 1 in 5 cancers were missed. Shield’s sensitivity for stage I to III cancer was 87.5% [2].
  • Most advanced precancerous lesions were missed. These are the large or high-risk polyps whose removal prevents cancer from developing. Blood tests found about 1 in 8 of them [2][4]. In PREEMPT CRC, the 12.5% result did not meet the study’s own prespecified target [4].
  • About 1 in 10 people without advanced neoplasia tested positive [2]. In PREEMPT CRC, 15.5% of positive results came from people who had advanced neoplasia on colonoscopy, so most positives turned out to be false alarms [4]. Each one leads to a colonoscopy.

The National Cancer Institute notes that blood-based tests have not yet been incorporated into clinical guidelines for first-line colorectal cancer screening [9].

How do blood tests compare with FIT, stool DNA tests and colonoscopy?

Stool tests and colonoscopy are the established colorectal screening options. The USPSTF 2021 recommendation covers adults 45 to 75, with selective screening from 76 to 85, and lists these strategies [7]:

TestWhat it looks forHow often (USPSTF 2021)
FIT (fecal immunochemical test)Hidden human blood in stoolEvery year
High-sensitivity guaiac FOBTHidden blood in stoolEvery year
Stool DNA with FITDNA changes and blood in stoolEvery 1 to 3 years
CT colonographyPolyps and tumors on a CT scanEvery 5 years
Flexible sigmoidoscopyThe lower colon, viewed directlyEvery 5 years, or every 10 years with yearly FIT
ColonoscopyThe whole colon, viewed directly, with polyps removedEvery 10 years

The ACS updated its guideline in May 2026. It starts screening at 45, lists stool tests and visual exams as preferred, and adds blood-based tests as a non-preferred option for people who are not willing to do either [5][6].

On accuracy, the USPSTF evidence review pooled the stool tests for detecting cancer [8]:

  • FIT: sensitivity 74%, specificity 94%, across 14 studies. The fecal occult blood test page explains how stool blood testing works;
  • stool DNA with FIT: sensitivity 93%, specificity 85%, across 4 studies;
  • high-sensitivity guaiac FOBT: sensitivity 50% to 75%, specificity 96% to 98%.

The same review found colonoscopy detected 89% of adenomas 6 mm or larger [8]. Colonoscopy is also the reference standard the other tests are judged against, and it removes polyps as it finds them. Figures from different studies are not a head-to-head trial, but the ACS reaches the same conclusion: blood tests “aren’t as good” at detecting precancerous growths as stool tests and visual exams [5].

Where a blood test does fit is as a way to get screened at all for someone who would otherwise skip it. The ACS guidance is explicit that this is its role: use it only if you are not willing to get a stool-based test or a visual exam, and get a colonoscopy if it is positive [5].

Can a multi-cancer test like Galleri detect colon cancer?

Galleri is a multi-cancer early detection (MCED) blood test, not a colorectal screening test. It reads methylation patterns in cell-free DNA to look for a signal shared by many cancer types, including colorectal cancer, and predicts where in the body the signal most likely came from.

The largest published US study is PATHFINDER 2, which tested 32,007 adults aged 50 or older without suspected cancer [11]. Across all cancers, Galleri detected 39.3% of cancers diagnosed in the following year, and 69.8% in a prespecified group of 12 cancers. Its specificity was 99.64%, and 60.3% of positive results led to a cancer diagnosis [11]. The study did not test whether screening with Galleri reduces cancer deaths, and its authors note that randomized trials are needed to show that [11].

As of November 2026, Galleri is not FDA approved. An FDA advisory panel voted in favor of approval on September 23, 2026, and GRAIL expects the FDA’s decision by early 2027 [12].

What Galleri adds is a look at many cancers that have no routine screening test. What it does not do is replace colonoscopy or a stool test: it is not designed to find precancerous polyps, and a negative result does not mean you can skip colorectal screening. The multi-cancer early detection test guide covers who Galleri fits and how to read a result.

Is CEA a blood test for colon cancer screening?

No. Carcinoembryonic antigen (CEA) is a tumor marker used after colorectal cancer has been diagnosed. The National Cancer Institute lists its use as checking the effect of treatment and detecting recurrence [14]. MedlinePlus states that CEA tests are not used to screen for or diagnose cancer [13].

CEA makes a poor screening test for two reasons. Smoking and several noncancerous conditions raise it, and many cancers, especially early ones, do not [13]. A normal CEA therefore does not rule out colon cancer, and a high one does not confirm it.

Mito offers a CEA blood test for people who already have a reason to track it, such as monitoring after colorectal cancer treatment with their oncologist. The CEA article covers the marker itself.

What routine blood work can hint at colon cancer?

A routine blood test can show the effect of a colon cancer without detecting the cancer itself. Colorectal cancers and some polyps bleed slowly into the bowel, often without visible blood in the stool. Over time that blood loss can cause iron deficiency anemia, which shows up on a CBC as low hemoglobin. The ACS notes that sometimes the first sign of colorectal cancer is a blood test showing a low red blood cell count [15].

Two results carry this clue:

  • Hemoglobin and red cell size on a CBC. Iron deficiency anemia shows up as low hemoglobin, often with small red blood cells. See symptoms of low hemoglobin.
  • Ferritin. Ferritin reflects the body’s iron stores. The American Gastroenterological Association (AGA) recommends a ferritin cutoff of 45 ng/mL, rather than 15 ng/mL, when diagnosing iron deficiency in people with anemia [16]. See symptoms of low ferritin.

Unexplained iron deficiency anemia in adults is a reason to look at the gut. The AGA recommends bidirectional endoscopy, meaning an upper endoscopy plus a colonoscopy, for men and postmenopausal women with iron deficiency anemia and no symptoms, and suggests it for premenopausal women [16].

The limits matter as much as the clue. Most anemia comes from causes other than cancer, such as heavy menstrual periods, low iron intake or other sources of blood loss. A normal CBC does not rule out colon cancer, because many cancers and polyps do not bleed enough to change it. Routine blood work is not colorectal screening. The is low hemoglobin a sign of cancer? article covers the other causes.

Mito’s Complete Blood Count (CBC) with Differential and Platelet Count and ferritin test cover both values.

When should you see a doctor?

Screening tests, including blood tests, are for people without symptoms. Symptoms call for a diagnostic evaluation, usually a colonoscopy, not a screening test. The ACS lists these signs of colorectal cancer [15]:

  • a change in bowel habits, such as diarrhea, constipation or narrower stools, that lasts more than a few days;
  • a feeling that you need to have a bowel movement that is not relieved by having one;
  • rectal bleeding with bright red blood, or blood that makes the stool look dark brown or black;
  • cramping or belly pain;
  • weakness and fatigue;
  • unintended weight loss.

Each of these has more common causes than cancer, but they are worth a visit, as is iron deficiency anemia with no clear cause [16]. See a doctor about screening if you are 45 or older and have never been screened. People with a family history of colorectal cancer or advanced polyps, inflammatory bowel disease or a hereditary syndrome are not in the average-risk group these blood tests are approved for, and usually need colonoscopy, sometimes starting earlier [1][6]. The personalized cancer screening plan after 40 walks through how risk changes the plan.

Where Mito fits

Mito does not sell Shield, SimpleScreen CRC, FIT, guaiac stool tests or stool DNA tests, and it does not perform colonoscopy. For colorectal screening, start with your primary care clinician or your insurer, who can order a stool test or refer you for colonoscopy.

Mito’s role sits around that screening:

  • Galleri adds a look across many cancers, most of which have no routine screening test. It is an addition to colorectal screening, not a substitute.
  • A CBC and ferritin can show iron deficiency anemia, a result that should lead to a conversation about a GI evaluation.
  • CEA is for tracking a known cancer, not for screening.

References

  1. US Food and Drug Administration: Premarket Approval P230009, Shield (approval order and supplements)
  2. Chung DC et al. A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening. N Engl J Med. 2024.
  3. US Food and Drug Administration: Premarket Approval P250029, SimpleScreen CRC
  4. Shaukat A et al. Clinical Validation of a Circulating Tumor DNA-Based Blood Test to Screen for Colorectal Cancer. JAMA. 2025.
  5. American Cancer Society: Colorectal Cancer Screening Tests
  6. American Cancer Society: Guideline for Colorectal Cancer Screening (revised May 27, 2026)
  7. US Preventive Services Task Force: Colorectal Cancer Screening Recommendation (May 18, 2021)
  8. Lin JS et al. Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2021.
  9. National Cancer Institute: Tests to Detect Colorectal Cancer and Polyps
  10. Medicare.gov: Blood-based biomarker tests for colorectal cancer screening
  11. Nabavizadeh N et al. Performance and safety of a multi-cancer early detection test: the PATHFINDER 2 study. Nat Med. 2026.
  12. GRAIL: Third Quarter 2026 Financial Results (November 4, 2026)
  13. MedlinePlus: CEA Test
  14. National Cancer Institute: Tumor Markers in Common Use
  15. American Cancer Society: Colorectal Cancer Signs and Symptoms
  16. Ko CW et al. AGA Clinical Practice Guidelines on the Gastrointestinal Evaluation of Iron Deficiency Anemia. Gastroenterology. 2020.

Frequently asked questions

Is there a blood test for colon cancer?

Yes. The FDA has approved two blood tests for colorectal cancer screening: Shield, approved in July 2024, and SimpleScreen CRC, approved in July 2026. Both are for adults 45 and older at average risk who have no symptoms. Both find most cancers but few precancerous polyps, and a positive result has to be followed by a colonoscopy.

Can a blood test replace a colonoscopy?

No. The FDA labels for Shield and SimpleScreen CRC say they are not a replacement for diagnostic colonoscopy or for surveillance colonoscopy in high-risk people. A colonoscopy can find and remove precancerous polyps in the same visit, which a blood test cannot do. The American Cancer Society says to use a blood test only if you are not willing to have a stool test or a visual exam.

How accurate is the Shield blood test?

In the ECLIPSE study of 7,861 average-risk adults, Shield detected 83% of the colorectal cancers that colonoscopy found and 13% of advanced precancerous lesions. About 10% of people without advanced neoplasia had a positive result. Those figures compare a single blood test against colonoscopy in the same people.

Can a CBC detect colon cancer?

Not directly. A complete blood count can show iron deficiency anemia, which slow bleeding from a colon cancer or polyp can cause. The American Cancer Society notes that sometimes the first sign of colorectal cancer is a blood test showing a low red blood cell count. Most anemia has other causes, and a normal CBC does not rule out colon cancer.

Does a high CEA mean colon cancer?

Not on its own. Smoking and several noncancerous conditions can raise CEA, and many early colon cancers do not raise it. CEA is used to check how a known colorectal cancer responds to treatment and to watch for recurrence. It is not used to screen for or diagnose cancer.

Does Galleri test for colon cancer?

Galleri looks for a shared cancer signal across many cancer types, and colorectal cancer is among them. It is not a colorectal screening test and has no FDA approval for any use as of November 2026. It is meant to be added to guideline screening such as colonoscopy or a stool test, not to stand in for it.

Screening lab tests

All for $9/month

Order any test or consult without joining. For $9/month, members unlock member prices, trend tracking, and year-round clinician guidance.

Mito Membership

$9 /mo

cancel anytime

Without membership

$0

pay as you go

At-cost pricing on labs, scans, and more

Standard pricing

Supplements at our cost NEW

On-demand clinician consults when you need guidance

$39 per 30 min
$99 per 30 min

Personalized action plans across supplements, exercise, nutrition, and sleep

AI health coaching to help you act on your results

Year-round medical support, with in-chat clinician escalation

All your health records in one personal vault, with trends and biological age tracking

Early access to new diagnostics and product releases

Galleri Multi-Cancer Early Detection Test

Your privacy choices

We use cookies to run our site, understand usage, and support marketing. You can anytime.

Your cart

Check eligibility

Answer a few quick health questions so we can check this test is right for you before you book. It takes about a minute.

Checkout

Complete your order

Send this cart as a gift

Each checkout sends one gift to one recipient. To gift another person, complete a separate checkout, or buy for a whole team or group in one payment.

Who it’s for

We’ll email the gift to the recipient and price it for their state.

Included membership

Member pricing on every test, a personalised action plan, trend tracking, and Mito Concierge for these months. Never auto-renews.

Who it’s from

Your name appears in the gift email. We’ll send the receipt and redemption link to your email.

Email delivery

Set your location

Choose the state where you'll get tested to see the tests and labs available there.

Mito Concierge

Hello

I can build you a panel, explain what your biomarkers mean, and find the cheapest lab near you.

Loading sign in…